key: cord-0772297-sy6ndvax authors: Praveen, Sharma; Ashish, Kumar; Anikhindi, ShriHari Anil; Naresh, Bansal; Vikas, Singla; Khare, Shivam; Anil, Arora title: Effect of COVID-19 on pre-existing liver disease: What Hepatologist should know? date: 2020-12-31 journal: J Clin Exp Hepatol DOI: 10.1016/j.jceh.2020.12.006 sha: 4504441b76f1af3d02d220ec9bde7405885f79c2 doc_id: 772297 cord_uid: sy6ndvax COVID-19 is characterized by predominant respiratory and gastrointestinal symptoms. Liver enzymes derangement is seen in 15-55% of the patients. Advanced age, hypertension, diabetes, obesity, malignancy and, cardiovascular disease predispose them to severe disease and the need for hospitalization. Data on preexisting liver disease in patients with COVID -19 is limited and most studies had only 3-8% of these patients. Patients with metabolic dysfunction associated fatty liver (MAFLD) had shown 4-6 fold increase in severity of COVID-19 and its severity and mortality increased in patients with higher fibrosis score. Patients with chronic liver disease had shown that cirrhosis is an independent predictor of severity of COVID-19 with increased hospitalization and mortality. Increase in Child Turcotte Pugh (CTP) score and model for end-stage liver disease (MELD) score increases the mortality in these patients. Few case reports had shown SARS-CoV-2 as an acute event in the decompensation of underlying chronic liver disease. Immunosuppression should be reduced prophylactically in patients with autoimmune liver disease and post-transplantation with no COVID-19. Hydroxychloroquine and remdesivir is found to be safe in limited studies in a patient with cirrhosis and COVID-19. For hepatologist cirrhosis with COVID-19 is a pertinent issue as the present pandemic will have severe disease in patients with chronic liver disease leading to more hospitalisation and decompensation. Coronaviruses are a family of viruses that can affect humans. The upper respiratory tract is the predominant site of infection though it can affect the liver and intestine also. While most patients with COVID-19 have mild disease, 10-15% of these patients need admission and of these few develop respiratory failure, septic shock, and/or multiple organ dysfunctions with a mortality rate which varies from 3-8%. 1,2 Liver involvement as suggested by impaired liver enzymes was seen in more than one third to half of patients with COVID-19. [3] [4] [5] [6] [7] Only 3-8% of the patients with pre-existing liver disease were seen and increased severity of COVID-19 in these patients had not yet been fully evaluated. [4] [5] [6] [7] [8] Published studies had not stated the severity of pre-existing liver disease so how COVID-19 affected these patients was not well known till the publication of a few studies in patients with chronic liver disease. 9-12. This short review assessed the effect of COVID-19 in patients with preexisting liver disease (compensated and decompensated) and special precaution which a Hepatologist should follow. The attachment of SARS-CoV-2 to the target cell is initiated by interactions between the spike glycoprotein (S) and its cognate receptor, angiotensin-converting enzyme 2 (ACE2). Following receptor engagement, SARS-CoV-2 S is processed by a plasma membraneassociated type II transmembrane serine protease, TMPRSS2, before membrane fusion which is essential to release the viral contents into the host cell cytosol. This hypothesis is supported by the dramatic increase of SARS-CoV-2 genomic RNAs viral load in human liver due to active viral replication in hepatic cells and cholangiocytes by SARS-CoV-2.The virus binds to target cells through ACE2 receptors however normal serum alkaline phosphatase (ALP) in the majority of patients is against this hypothesis. Cytokine storm hypothesis includes immune-mediated damage due to the severe inflammatory response following COVID-19 infection. This hypothesis is supported by significantly elevated markers of inflammation like C reactive protein (CRP), serum ferritin, LDH, IL-6, and IL-2. Post-mortem liver biopsy in patients who died from COVID-19 showed only microvesicular steatosis, accompanied by hyperactivation of T cells suggesting that liver injury is likely immunemediated rather than direct cytopathic damage. Ischemic damage of liver hypothesis postulated that as a majority of sick patients were on the ventilator and inotropic support so deranged liver enzymes could be due to ischemic hepatitis. However, aspartate and alanine aminotransferase (AST /ALT) rise is one to two times the upper limit of normal which is against ischemic or hypoxic liver injury. Another probable reason is drug-induced liver injury (DILI) as a majority of the patients are on several drugs like lopinavir/ritonavir, remdesivir, chloroquine, tocilizumab, and Chinese traditional medicine, which have some hepatotoxic effects. 15, 16 There is a paucity of patients with pre-existing liver disease in studies on COVID-19 and characteristics of these patients according to Child's status or MELD score had not been evaluated separately in these studies. 3 MELD score with (European Foundation for the study of chronic liver failure organ failure and cirrhosis) CLIF-C and CLIF-OF as predictors of increased mortality. These studies (Table-1) had shown that underlying pre-existing liver disease is a risk factor for increased severity of COVID-19 and these patients should be looked upon by trained hepatologist and Internist. There is limited data on chronic hepatitis B and the severity of COVID- 19 . However, in both categories serum, AST/ALT and total bilirubin were less than two times the upper limit of normal. In this pooled study they could not assess whether the coexistence of chronic liver comorbidities increases susceptibility to liver injury in SARS-CoV-2 infection. Consumption of alcohol has increased in the present pandemic due to various reasons like home quarantine, stress related to COVID like the loss in business, job insecurity, and myth that alcohol consumption will reduce chances of getting COVID in the present pandemic. There is very limited data on the effect of COVID-19 in patients with alcoholic liver disease or in patients with alcoholic hepatitis. 12, [19] [20] [21] However limited studies in patients with cirrhosis who had enrolled patients with alcohol-related cirrhosis had shown increased mortality in these patients as in other patients with cirrhosis. 12, 20, 21 Patients with alcohol-J o u r n a l P r e -p r o o f related disease often had associated co-morbidities such as obesity, diabetes mellitus and chronic kidney disease, which also increase the risk for complications in COVID- 19. 23 Although there is no specific guidelines on the management of alcoholic hepatitis during this The term non-alcoholic fatty liver disease These studies suggest patients with MAFLD had higher chances of getting severe COVID-19. MAFLD patients are more likely to have abnormal AST and ALT, had higher viral shedding time, more liver injury during the hospital stay. MAFLD with significant fibrosis is another risk factor for the severity of COVID-19 compared to intermediate or no fibrosis patients. (Table-2 ) . Due to a lack of data in patients with autoimmune liver diseases (autoimmune hepatitis AIH, There is a scarcity of data on decompensated cirrhosis and COVID The COVID-19 pandemic has had enormous impacts on all elective surgeries all over the world and this has also affected liver transplantation (LT). Diversion of hospital resources which includes nurses, paramedical staff, and hospital beds including ICU to COVID-19 patients has affected LT program. Risk of LT recipients or live donors acquiring SARS-COV-2 infection during hospitalization and its impact in post LT period is also a major concern. How immunosuppression therapy will affect the course of liver transplant recipient in the initial days and later in the case of SARS-COV-2 infection is unclear from the present data available. Becchetti et al 38 in a European multicentre prospective study of liver transplant recipients (n=57) concluded that COVID-19 was associated with an overall and in-hospital fatality rate of 12% (95% CI 5% to 24%) and 17% (95% CI 7% to 32%), respectively. Immunosuppression In the majority of patients with COVID-19 and no coexisting co-morbidities, supportive therapy is enough for complete recovery and no specific drug is required. Patients with MAFLD and cirrhosis are independent predictors of severity of COVID-19 and these patients should be closely monitored and admitted if needed. Several drugs, namely chloroquine, hydroxychloroquine, remdesivir, favipiravir, and lopinavir/ritonavir are being used in the treatment of COVID-19 with a variable degree of hepatotoxicity and success. Drugs have been tried in patients with COVID-19 with cirrhosis and MAFLD but data is limited (Table-3) . Table-2 Studies on MAFLD and COVID-19 Table- A Novel Coronavirus from Patients with Pneumonia in China Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Clinical Characteristics of Coronavirus Disease 2019 in China Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city Risk Factors for Mortality of COVID-19 Patients With Pre-Existing Cirrhosis: A Multicentre Cohort Study. Gut High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Cell Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids Pathological findings of COVID-19 associated with acute respiratory distress syndrome COVID-19: Abnormal liver function tests Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis Chronic liver disease is not associated with severity or mortality in Coronavirus disease 2019 (COVID-19): a pooled analysis Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID Successful treatment of patients with hepatitis C in rural and remote Western Australia via telehealth Using telehealth to enable patient-centered care for liver transplantation An automated telephone monitoring system to identify patients with cirrhosis at risk of re-hospitalization